Comparison of “pediatric” and “adult” chemotherapy regimens
| Feature . | Typical pediatric ALL regimen . | Typical adult ALL regimen . |
|---|---|---|
| Asparaginase | Higher cumulative dose | Lower cumulative dose or no use through therapy |
| Vincristine | Higher cumulative dose | Lower cumulative dose |
| Intrathecal therapy | Higher cumulative dose | Lower cumulative dose |
| Steroid | Higher or similar cumulative dose | Lower or similar cumulative dose |
| Anthracycline | Lower cumulative dose | Higher cumulative dose |
| Cyclophosphamide | Lower cumulative dose | Higher cumulative dose |
| Cranial radiation | Variable/not commonly recommended | Variable |
| Hospitalization | Induction only | Often with each cycle |
| Adverse effects | More asparaginase-related toxicities | More myelosuppression-related toxicities |
| Feature . | Typical pediatric ALL regimen . | Typical adult ALL regimen . |
|---|---|---|
| Asparaginase | Higher cumulative dose | Lower cumulative dose or no use through therapy |
| Vincristine | Higher cumulative dose | Lower cumulative dose |
| Intrathecal therapy | Higher cumulative dose | Lower cumulative dose |
| Steroid | Higher or similar cumulative dose | Lower or similar cumulative dose |
| Anthracycline | Lower cumulative dose | Higher cumulative dose |
| Cyclophosphamide | Lower cumulative dose | Higher cumulative dose |
| Cranial radiation | Variable/not commonly recommended | Variable |
| Hospitalization | Induction only | Often with each cycle |
| Adverse effects | More asparaginase-related toxicities | More myelosuppression-related toxicities |